Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

Jean Bronstein, 1	R.N.,	M.S.
-------------------	-------	------

Committee:

Psychopharmacologic Drugs Advisory Committee

Meeting Date: December 13, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the committee's discuss ions of the results of the FDA ongoing meta-analysis of suicidality data from adult antidepressant trials. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude		
Stock/Bond	Affected Firm	Valued from \$50,001 to \$100,000		
Stock	Affected Firm	Valued from \$5,001 to \$25,000		
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.				
/s/ Signature of SGE	11/6/00 Date	5		